Claims
- 1. A compound of formula I: whereinX is ORbd, wherein Rbd is hydrogen or C1-3alkyl, or NRbeRbf in which Rbe and Rbf are independently hydrogen, C1-4alkyl, C1-4hydroxyalkyl or C1-4alkanoyl, or the radical NRbeRbf is pyrrolidino, piperidino or morpholino; and Rbg is hydrogen or C1-4alkyl; with the proviso that X is not NHCH3; and wherein Q2 is a nitrogen-linked five-membered aromatic ring containing 1-4 nitrogens, which is substituted at a ring position adjacent to the nitrogen-link by a group Q5; Q3 is hydrogen or C1-3alkyl; Q4 is phenyl which may bear one or two substituents independently selected from halo, trifluoromethyl, hydroxy, C1-3alkoxy, C1-3alkyl and methylenedioxy; or Q4 is thienyl, imidazolyl, benzo[b]thiophenyl or naphthyl any of which may bear a halo substituent; or Q4 is biphenylyl; or Q4 is carbon-linked indolyl which may bear a benzyl substituent at the 1-position; and Q5 is selected from the group consisting of phenyl, benzyl, phenethyl and naphthyl, wherein any phenyl ring or naphthyl may bear one or more substituents selected from C1-3alkyl, C1-3alkoxy, methylenedioxy, halogeno, hydroxy, C1-4acyloxy and NRARB in which RA and RB are independently hydrogen or C1-3alkyl, or RA is hydrogen or C1-3alkyl and RB is C1-4acyl; or the N-oxide of a piperidino nitrogen indicated by Δ; or a pharmaceutically acceptable salt thereof; or a quaternary ammonium salt thereof in which the piperidino nitrogen indicated by Δ is a quadricovalent ammonium nitrogen wherein the fourth radical on the nitrogen R1 is C1-4alkyl or benzyl and the associated counterion A is a pharmaceutically acceptable anion.
- 2. A compound according to claim 1 having the structure wherein Q2 and Q5 have any of the meanings given in claim 1.
- 3. A compound according to claim 1 wherein X is ORbd.
- 4. A compound according to claim 1 wherein X is NH2 or N(CH3)2.
- 5. A compound according to claim 1 wherein:p is 0; Rbb is phenyl; and Rbc hydroxy or —N(H)C(═O)CH3.
- 6. A pharmaceutical composition, comprisinga compound according to claim 1; and a pharmaceutically acceptable diluent or carrier.
- 7. A method of treating asthma and related conditions involving bronchoconstriction, increased microvascular permeability, vasodilation or activation of mast cells, comprising the step of administering an effective amount of a compound according to claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9508786 |
Apr 1995 |
GB |
|
9508786 |
Apr 1995 |
GB |
|
Parent Case Info
This application is a division of Ser. No. 09/519,307, filed Mar. 6, 2000 now U.S. Pat. No. 6,235,757 which is a div. of Ser. No. 08/635,161, filed Apr. 23, 1996, now U.S. Pat. No. 5,889,024 claims priority of GB 9508786 filed on Apr. 29, 1995.
US Referenced Citations (8)
Number |
Name |
Date |
Kind |
4782061 |
Kruse et al. |
Nov 1988 |
A |
5236921 |
Emonds-Alt et al. |
Aug 1993 |
A |
5300648 |
Emonds-Alt et al. |
Apr 1994 |
A |
5340822 |
Emonds-Alt et al. |
Aug 1994 |
A |
5411971 |
Emonds-Alt et al. |
May 1995 |
A |
5434158 |
Shah |
Jul 1995 |
A |
5731309 |
Bernstein et al. |
Mar 1998 |
A |
5889024 |
Miller et al. |
Mar 1999 |
A |
Foreign Referenced Citations (24)
Number |
Date |
Country |
2029275 |
May 1991 |
CA |
2067924 |
Nov 1992 |
CA |
2090785 |
Sep 1993 |
CA |
0190472 |
Aug 1986 |
EP |
0428434 |
May 1991 |
EP |
0474561 |
Mar 1992 |
EP |
0512901 |
Nov 1992 |
EP |
0512902 |
Nov 1992 |
EP |
0515240 |
Nov 1992 |
EP |
0559538 |
Sep 1993 |
EP |
0625509 |
Nov 1994 |
EP |
0630887 |
Dec 1994 |
EP |
0680962 |
Nov 1995 |
EP |
709376 |
Jan 1996 |
EP |
739891 |
Oct 1996 |
EP |
2248449 |
Apr 1992 |
GB |
WO 9410146 |
May 1994 |
WO |
WO 9429309 |
Dec 1994 |
WO |
WO 9505377 |
Feb 1995 |
WO |
WO 9512577 |
May 1995 |
WO |
WO 9515961 |
Jun 1995 |
WO |
WO 9516682 |
Jun 1995 |
WO |
923177 |
Jan 1993 |
ZA |
923178 |
Jan 1993 |
ZA |
Non-Patent Literature Citations (4)
Entry |
A. Graham et al., “Isolation and Characterisation of the Human Lung NK-2 Receptor Gene Using Rapid Amplification of cDNA Ends”m Biochemical and Biophysical Research Communications, (1991), vol. 177, No. 1, 8-16. |
X. Emonds-Alt et al., “Pharamacological Profile and Chemical Synthesis of SR 48968, a Non-Peptide Antagonist of the Neurokinin A (NK2) Receptor”, Bioorganic & Medicinal Chemistry Letters, (1993), vol. 3, No. 5, 925-930. |
D. Aharony et al., “Pharamacologic Characterization of the Novel Ligand [4,5-3H-LEU9]Neurokinin-A Binding to NK-2 Receptors on Hamster Urinary Bladder Membranes”, Neuropeptides, (1992), 23, 121-130. |
M. Needham et al., “LCR/MEL: A versatile System for High-Level Expression of Hertologous Proteins in Erythroid Cells”, Nucleic Acids Research, (1992), vol. 20, No. 5, 997-1003. |